Last reviewed · How we verify
Perampanel 1 week titration
At a glance
| Generic name | Perampanel 1 week titration |
|---|---|
| Also known as | Fycompa |
| Sponsor | Kimford Jay Meador |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Perampanel Titration and Cognitive Effects (PHASE4)
- Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy (PHASE2)
- A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children
- A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs) (PHASE2)
- Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs (PHASE2)
- Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations (PHASE3)
- Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN) (PHASE2)
- An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perampanel 1 week titration CI brief — competitive landscape report
- Perampanel 1 week titration updates RSS · CI watch RSS
- Kimford Jay Meador portfolio CI